Receive our newsletter – data, insights and analysis delivered to you
June 24, 2009

Cell Therapeutics Submits NDA for Pixantrone Lymphoma Drug

Cell Therapeutics (CTI) has completed the submission of New Drug Application (NDA) to the US Food and Drug Administration (FDA) for pixantrone, a new drug to treat relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). CTI has requested priority review for the drug, which if g

By cms admin

Cell Therapeutics (CTI) has completed the submission of New Drug Application (NDA) to the US Food and Drug Administration (FDA) for pixantrone, a new drug to treat relapsed or refractory aggressive non-Hodgkin’s lymphoma (NHL).

CTI has requested priority review for the drug, which if granted, could lead to an approval decision from FDA in the fourth quarter of 2009.

CTI CEO James Bianco said that this is a major milestone for CTI and is the cornerstone of a turnaround strategy for the company in meeting its goals of becoming a profitable operating business.

“This represents a significant advance in the treatment of patients with relapsed/refractory aggressive NHL; a patient population which the FDA has acknowledged represents an unmet medical need,” Bianco said.

The NDA application is based on the PIX 301 EXTEND trial, which involved a Phase III single-agent trial of pixantrone for patients with relapsed or refractory, aggressive NHL, who had received two or more prior therapies and who were sensitive to treatment with anthracyclines.

The trial patients were randomised to receive either pixantrone or another single-agent drug, currently used for the treatment of this patient population as selected by the physician.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU